Wedelin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341602

CAS#: 89353-61-7

Description: Wedelin is a biochemical.


Chemical Structure

img
Wedelin
CAS# 89353-61-7

Theoretical Analysis

MedKoo Cat#: 341602
Name: Wedelin
CAS#: 89353-61-7
Chemical Formula: C40H55NO13
Exact Mass: 757.37
Molecular Weight: 757.874
Elemental Analysis: C, 63.39; H, 7.32; N, 1.85; O, 27.44

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Wedelin.

IUPAC/Chemical Name: 3-beta-28-(beta-D-Glucopyranosyloxy)-28-oxo-olean-12-en-3-yl-beta-D-galactopyranosiduronic acid

InChi Key: KORXNOWCVVACSW-YABYRKKLSA-N

InChi Code: InChI=1S/C40H55NO13/c1-21(2)16-28(43)41-30-32(54-29(44)11-10-23-8-6-5-7-9-23)31(45)25(19-42)53-34(30)52-24-17-37(4)26-13-15-39(51)20-38(26,33(46)22(39)3)14-12-27(37)40(18-24,35(47)48)36(49)50/h5-9,21,24-27,30-34,42,45-46,51H,3,10-20H2,1-2,4H3,(H,41,43)(H,47,48)(H,49,50)/t24-,25+,26-,27-,30+,31+,32+,33-,34+,37-,38+,39-/m0/s1

SMILES Code: C=C([C@@](CC1)(O)C2)[C@H](O)[C@@]32CC[C@]4([H])C(C(O)=O)(C(O)=O)C[C@@H](O[C@H]5[C@H](NC(CC(C)C)=O)[C@H]([C@@H]([C@@H](CO)O5)O)OC(CCC6=CC=CC=C6)=O)C[C@@]4(C)[C@@]31[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 757.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gennemark P, Wedelin D. ODEion--a software module for structural identification of ordinary differential equations. J Bioinform Comput Biol. 2014 Feb;12(1):1350015. doi: 10.1142/S0219720013500157. Epub 2013 Nov 12. PubMed PMID: 24467754.

2: Gennemark P, Wedelin D. Benchmarks for identification of ordinary differential equations from time series data. Bioinformatics. 2009 Mar 15;25(6):780-6. doi: 10.1093/bioinformatics/btp050. Epub 2009 Jan 28. PubMed PMID: 19176548; PubMed Central PMCID: PMC2654804.

3: Gennemark P, Wedelin D. Efficient algorithms for ordinary differential equation model identification of biological systems. IET Syst Biol. 2007 Mar;1(2):120-9. PubMed PMID: 17441553.

4: Gennemark P, Nordlander B, Hohmann S, Wedelin D. A simple mathematical model of adaptation to high osmolarity in yeast. In Silico Biol. 2006;6(3):193-214. PubMed PMID: 16922683.

5: Landgren O, Axdorph U, Fears TR, Porwit-MacDonald A, Wedelin C, Björkholm M. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol. 2006 Aug;17(8):1290-5. Epub 2006 Jun 1. PubMed PMID: 16740597.

6: Landgren O, Porwit MacDonald A, Tani E, Czader M, Grimfors G, Skoog L, Ost A, Wedelin C, Axdorph U, Svedmyr E, Björkholm M. A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas. Hematol J. 2004;5(1):69-76. PubMed PMID: 14745433.

7: Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, Grimfors G, Björkholm M. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003 Apr;88(4):438-44. PubMed PMID: 12681971.

8: Gårdlund B, Rimeika D, Wedelin B, Laska J. Preoperative bacterial colonization of the upper airways does not predict postoperative airway infection in children. Acta Paediatr. 1998 Apr;87(4):375-7. PubMed PMID: 9628289.

9: Tullgren O, Grimfors G, Holm G, Johansson B, Svedmyr E, Wedelin C, Mellstedt H, Merk K, Björkholm M. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up. Cancer. 1991 Aug 15;68(4):768-75. PubMed PMID: 1855177.

10: Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Liliemark J, Lindeberg A, Lindquist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt AM, Sundström C, Wadman B, Wedelin C, Udén AM, Öberg G, Öst Å. A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia. Leuk Lymphoma. 1991;3(5-6):355-64. doi: 10.3109/10428199109070279. PubMed PMID: 27467426.

11: Mellstedt H, Frödin JE, Lindemalm C, Masucci G, Merk K, Pettersson D, Ragnhammar P, Steinitz M, Wedelin C, Wersäll P, et al. Biologic response modifiers in the treatment of gastrointestinal malignancies. Scand J Gastroenterol. 1989 Apr;24(3):257-68. Review. PubMed PMID: 2660246.

12: Mellstedt H, Frödin JE, Masucci G, Lindemalm C, Wedelin C, Christensson B, Shetye J, Biberfeld P, Lefvert AK, Pihlstedt P, et al. Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas. Acta Chir Scand Suppl. 1989;549:63-70. PubMed PMID: 2929214.

13: Wedelin C, Björkholm M, Mellstedt H, Gahrton G, Holm G. Clinical findings and prognostic factors in chronic myeloid leukemias. Acta Med Scand. 1986;220(3):255-60. PubMed PMID: 3465200.

14: Ohqvist G, Settergren G, Tuppurainen T, Anjou Lindskog E, Fischerström A, Torssell L, Wedelin B, Wickerts CJ. Circulatory effects of pancuronium and alcuronium in patients with coronary artery stenosis. Acta Anaesthesiol Scand. 1985 Jan;29(1):22-5. PubMed PMID: 3872001.

15: Björkholm M, Wedelin C, Holm G, Essy-Ehsing B. Familial longevity and prognosis in Hodgkin's disease. Cancer. 1984 Sep 15;54(6):1088-92. PubMed PMID: 6467134.

16: Wedelin C, Björkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H. Prognostic factors in Hodgkin's disease with special reference to age. Cancer. 1984 Mar 1;53(5):1202-8. PubMed PMID: 6692308.

17: Wedelin C, Björkholm M, Johansson B, Mellstedt H. Clinical and laboratory findings in untreated patients with Hodgkin's disease with special reference to age. Med Oncol Tumor Pharmacother. 1984;1(1):33-41. PubMed PMID: 6544357.

18: Anjou-Lindskog E, Broman L, Holmgren A, Wedelin B. Effects of prenalterol on central haemodynamics and VA/Q distribution early after open-heart surgery. Acta Anaesthesiol Scand. 1983 Apr;27(2):142-8. PubMed PMID: 6837248.

19: Björkholm M, Wedelin C, Holm G, Ericsson H, Nilsson P, Mellstedt H. Lymphocytotoxic serum factors and lymphocyte functions in untreated Hodgkin's disease. Cancer. 1982 Nov 15;50(10):2044-8. PubMed PMID: 7127249.

20: Björkholm M, Wedelin C, Holm G, Ogenstad S, Johansson B, Mellstedt H. Immune status of untreated patients with Hodgkin's disease and prognosis. Cancer Treat Rep. 1982 Apr;66(4):701-9. PubMed PMID: 7074640.